Revmoxicam (meloxicam) tablets 7.5 mg. №20

Description

Revmoxicam (meloxicam) tablets 7.5 mg. №20

Composition

active ingredient: meloxicam;

1 tablet contains meloxicam – 7.5 mg or 15 mg (in terms of 100% anhydrous substance);

excipients: lactose, monohydrate; cellulose microcrystalline; povidone; sodium citrate; crospovidone; silicon dioxide colloidal anhydrous; magnesium stearate.

Dosage form

Tablets.

Basic physical and chemical properties: tablets of round shape with a flat surface, chamfer and risk, yellow.

Pharmacological group

Non-steroidal anti-inflammatory drugs and antirheumatic drugs.
ATX code M01A C06.

Pharmacological properties

Rheumoxicam is a non-steroidal anti-inflammatory drug (NSAID) of the enolic acid class with anti-inflammatory, analgesic and antipyretic effects.

Meloxicam showed high anti-inflammatory activity in all standard models of inflammation. As with other NSAIDs, its exact mechanism of action remains unknown. However, there is a common development mechanism for all NSAIDs (including meloxicam): inhibition of the biosynthesis of prostaglandins, which are inflammatory mediators.

Pharmacological properties

Non-steroidal anti-inflammatory (NSAID) and antirheumatic pharmaceuticals.
It has analgesic (pain relieving), antiphlogistic (anti-inflammatory) and antipyretic (antipyretic) effects.

Indications

Revmoxicam tablets 7.5 mg are used for the symptomatic treatment of pain syndrome with:

• ankylosing spondylitis;
• arthrosis;
• osteoarthritis;
• degenerative joint diseases;
• rheumatoid arthritis.

Contraindications

Revmoxicam tablets are prohibited in case of hypersensitivity to them or to other NSAIDs.
Also contraindications to the use of Revmoxicam are:

• blood clotting disorders, bleeding;
• the presence of ulcers / perforation in the digestive tract;
• severe liver failure;
• active Crohn’s disease / ulcerative colitis;
• severe renal failure without hemodialysis;
• children up to age twelve;
• severe uncontrolled heart failure.

Application during pregnancy and lactation

It is forbidden to use Revmoxicam tablets during these periods.

Method of administration and dosage

Apply orally.

The total amount of the drug Revmoxicam tablets 7.5 mg should be taken as a single dose with water or other liquid during meals.

Adverse reactions can be minimized by using the lowest effective dose for the shortest duration of treatment necessary to control symptoms. The patient’s need for symptomatic relief and response to treatment should be periodically assessed.

• Exacerbation of osteoarthritis: 7.5 mg/day (1 7.5 mg tablet or half a 15 mg tablet). If necessary, the dose can be increased to 15 mg / day (1 tablet 15 mg or 2 tablets 7.5 mg).
• Rheumatoid arthritis, ankylosing spondylitis: 15 mg/day (1 tablet 15 mg or 2 tablets 7.5 mg).
• According to the therapeutic effect, the dose can be reduced to 7.5 mg / day (1 tablet 7.5 mg or half a tablet 15 mg).

Overdose

For acute drug overdose Revmoxicam is characterized by: drowsiness, abdominal pain, nausea, lethargy, vomiting. Bleeding from the digestive tract is also possible. In severe poisoning, hypertension, liver dysfunction, acute renal failure, cardiac arrest, coma may occur.

Treatment in case of an overdose with Revmoxicam tablets provides for the withdrawal of the drug, gastric lavage and symptomatic treatment. There is no specific antidote.

Side effects

Side effects that may occur during the use of the pharmaceutical drug Revmoxicam include the following: stomatitis, dizziness, dyspepsia, palpitations, esophagitis, flatulence, headache, edema, tinnitus, drowsiness, mood changes, conjunctivitis, confusion, visual disturbances, nausea, colitis, increased blood pressure, hot flashes, gastritis, disorientation, gastroduodenal ulcer, acute renal failure, vomiting, photosensitivity, liver dysfunction, abdominal pain, pruritus, belching, gastrointestinal perforation, constipation / diarrhea, skin rashes, bleeding from the digestive tract.

Changes in the blood picture may also occur – thrombocytopenia (a decrease in the number of platelets), leukopenia (a decrease in the number of white blood cells), anemia (a decrease in the number of red blood cells).
Possible anaphylactic reactions, polymorphic erythema, Stevens-Johnson syndrome, angioedema, urticaria.
Patients who are allergic to NSAIDs may develop an asthma attack.